[Hemodialysis prospective multicentric quality study].
In medicine a considerable amount of resources are used in research, but very little attention is paid to ensuring that the findings of research are implemented in routine clinical practice. This prospective study has the aim to evaluate the efficiency of some clinical management strategies (feedback, benchmarking and improving plans) on haemodialysis treatment results in 4 different dialysis centres. We collected consensus data related to haemodialysis results every 6-8 months and informed each centre about its own results (feedback) and how these related to the others(benchmarking). We designed improving plans for any bad result detected. By the end of two years of follow up, 294 patients had been included in the study. The results obtained at the end of the study had improved in comparison with those obtained at the beginning (statistically significant) for the following indicators: % of patients with Hb< 11 g/dl, % patients with Kt/v < 1.2, mean Kt/v, mean albumin, % patients with albumin< 3.5 g/dl y % patients with C reactive protein (CRP) > 5 mg/dl. No statistical changes were found in: mean erythropoietin (EPO) doses, blood pressure (BP), phosphorus plasmatic,calcium-phosphorus product, parathormone (PTHi) and vascular access distribution. We explained the absence of any improvement because of adequate start indicators in some areas (BP and vascular access), therapy with limited efficiency (calcitriol, calcium carbonate and others), lack of support resources (dietetic unit) or inadequate design/implementation of improving plans.In conclusion, our intervention illustrates that combined clinical management strategies(feedback, benchmarking and improving plans) are efficiency in improving some areas of haemodialysis treatment (anaemia, dialysis dose, nutrition and inflammation), although it does not improve calcium phosphate metabolism related indicators.
Parra
E
E
Fundación Hospital Calahorra, Unidad de Nefrología, Carretera Logroño s/n, 26500 Calahorra, La Rioja. eparra@fhcalahorra.com
Ramos
R
R
Betriú
A
A
Paniagua
J
J
Belart
M
M
Martín
F
F
Martínez
T
T
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D019985:Benchmarking / Q000706:statistics & numerical data*; D001794:Blood Pressure; D002097:C-Reactive Protein / Q000032:analysis; D002118:Calcium / Q000097:blood; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D002408:Catheters, Indwelling; D015897:Comorbidity; D004921:Erythropoietin / Q000627:therapeutic use; D005246:Feedback; D005260:Female; D005500:Follow-Up Studies; D006436:Hemodialysis Units, Hospital / Q000706:statistics & numerical data*; D006801:Humans; D007249:Inflammation / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000453:epidemiology / Q000628:therapy; D008297:Male; D044342:Malnutrition / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011446:Prospective Studies; D011785:Quality Assurance, Health Care; D006435:Renal Dialysis / Q000706:statistics & numerical data*; D013030:Spain / Q000453:epidemiology
D010281:Parathyroid Hormone; D004921:Erythropoietin; D010758:Phosphorus; D002097:C-Reactive Protein; D002118:Calcium